254 related articles for article (PubMed ID: 35065924)
1. CKAP2L, transcriptionally inhibited by FOXP3, promotes breast carcinogenesis through the AKT/mTOR pathway.
Chi F; Chen L; Jin X; He G; Liu Z; Han S
Exp Cell Res; 2022 Mar; 412(2):113035. PubMed ID: 35065924
[TBL] [Abstract][Full Text] [Related]
2. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
[TBL] [Abstract][Full Text] [Related]
3. LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway.
Bi QJ; Men XJ; Han R; Li GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3067-3073. PubMed ID: 29863252
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB).
Ma Q; Gao Y; Xu P; Li K; Xu X; Gao J; Qi Y; Xu J; Yang Y; Song W; He X; Liu S; Yuan X; Yin W; He Y; Pan W; Wei L; Zhang J
Biomed Res Int; 2019; 2019():3235021. PubMed ID: 31011573
[TBL] [Abstract][Full Text] [Related]
5. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway.
Huang YK; Kang WM; Ma ZQ; Liu YQ; Zhou L; Yu JC
Carcinogenesis; 2019 Apr; 40(2):370-379. PubMed ID: 30371738
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
7. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
8. SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling.
Xu M; Zhang X; Zhang S; Piao J; Yang Y; Wang X; Lin Z
Aging (Albany NY); 2020 Dec; 13(1):1032-1050. PubMed ID: 33293473
[TBL] [Abstract][Full Text] [Related]
9. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
[TBL] [Abstract][Full Text] [Related]
10. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway.
Yao Y; Zhou D; Shi D; Zhang H; Zhan S; Shao X; Sun K; Sun L; Wu G; Tian K; Zhu X; He S
Biomed Pharmacother; 2019 Mar; 111():993-1004. PubMed ID: 30841479
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
[TBL] [Abstract][Full Text] [Related]
12. The miRNA mir-582-3p suppresses ovarian cancer progression by targeting AKT/MTOR signaling
Dai T; Liang J; Liu W; Zou Y; Niu F; Li M; Zhang H; Li C; Fan M; Cui G
Bioengineered; 2021 Dec; 12(2):10771-10781. PubMed ID: 34793263
[TBL] [Abstract][Full Text] [Related]
13. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling.
Zhan CH; Ding DS; Zhang W; Wang HL; Mao ZY; Liu GJ
Bioengineered; 2022 Apr; 13(4):8478-8489. PubMed ID: 35322748
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of microRNA-190 inhibits migration, invasion, epithelial-mesenchymal transition, and angiogenesis through suppression of protein kinase B-extracellular signal-regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer.
Sun G; Liu M; Han H
J Cell Physiol; 2019 Aug; 234(10):17824-17838. PubMed ID: 30993707
[TBL] [Abstract][Full Text] [Related]
15. CKAP2L, a crucial target of miR-326, promotes prostate cancer progression.
Li Q; Yan M; Wang C; Wang K; Bao G
BMC Cancer; 2022 Jun; 22(1):666. PubMed ID: 35715760
[TBL] [Abstract][Full Text] [Related]
16. MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.
Li Z; Li C; Wu Q; Tu Y; Wang C; Yu X; Li B; Wang Z; Sun S; Sun S
Cell Death Dis; 2021 Jan; 12(1):97. PubMed ID: 33462219
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2.
Xiu DH; Liu GF; Yu SN; Li LY; Zhao GQ; Liu L; Li XF
J Exp Clin Cancer Res; 2019 Feb; 38(1):94. PubMed ID: 30791958
[TBL] [Abstract][Full Text] [Related]
18. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
Zhang Y; Cheng H; Li W; Wu H; Yang Y
Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
[TBL] [Abstract][Full Text] [Related]
19. MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R.
Wang B; Wang H; Yang Z
PLoS One; 2012; 7(10):e47053. PubMed ID: 23056576
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
